Patents by Inventor Wang Shen

Wang Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF HEPATITIS C VIRUS POLYMERASE
    Publication number: 20120183496
    Abstract: The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R1A, R1B, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
    Type: Application
    Filed: December 16, 2011
    Publication date: July 19, 2012
    Applicant: COCRYSTAL DISCOVERY, INC.
    Inventors: Sam SK Lee, Wang Shen, Xiaoling Zheng, Irina C. Jacobson
  • PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS
    Publication number: 20120115811
    Abstract: Provided herein are compounds of formula I: wherein A, B, X, R1, R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions.
    Type: Application
    Filed: February 12, 2010
    Publication date: May 10, 2012
    Applicant: Amgen Inc.
    Inventors: Xiaohui Du, Zice Fu, Jonathan B. Houze, Xian Yun Jiao, Yong-Jae Kim, Leping Li, Jinqian Liu, Mike Elias Lizarzaburu, Julio C. Medina, Wang Shen, Simon Turcotte, Ming Yu
  • Modulators of Cellular Adhesion
    Publication number: 20120035154
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Type: Application
    Filed: September 1, 2011
    Publication date: February 9, 2012
    Applicant: SARcode Bioscience, Inc.
    Inventors: Wang SHEN, Kenneth BARR, Johan D. OSLOB, Min ZHONG
  • Compositions and methods for treatment of eye disorders
    Patent number: 8084047
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: December 27, 2011
    Assignee: Sarcode Bioscience Inc.
    Inventors: Wang Shen, Johan D. Oslob, Kenneth Barr, Min Zhong
  • Modulators of cellular adhesion
    Patent number: 8071617
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: December 6, 2011
    Assignee: SARcode Bioscience Inc.
    Inventors: Wang Shen, Kenneth Barr, Johan D. Oslob, Min Zhong
  • Substituted biphenyl GPR40 modulators
    Patent number: 8030354
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 4, 2011
    Assignee: Amgen Inc.
    Inventors: Sean P. Brown, Qiong Cao, Paul John Dransfield, Xiaohui Du, Zice Fu, Jonathan Houze, Xian Yun Jiao, Yong-Jae Kim, Todd J. Kohn, SuJen Lai, An-Rong Li, Daniel Lin, Jiwen Liu, Jian Luo, Julio C. Medina, Jeffrey D. Reagan, Vatee Pattaropong, Margrit Schwarz, Wang Shen, Yongli Su, Gayathri Swaminath, Marc Vimolratana, Yingcai Wang, Yumei Xiong, Li Yang, Ming Yu, Jie Zhang, Liusheng Zhu
  • Heterocyclic GPR40 modulators
    Patent number: 8003648
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: August 23, 2011
    Assignee: Amgen Inc.
    Inventors: Hilary Beck, Paul Dransfield, Zice Fu, Jonathan B. Houze, XianYun Jiao, Todd J. Kohn, SuJen Lai, Jinqian Liu, Jiwen Liu, Zhihua Ma, Julio C. Medina, Michael J. Schmitt, Rajiv Sharma, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang
  • SPIROCYCLIC GPR40 MODULATORS
    Publication number: 20110190330
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I?A or I?B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: October 13, 2009
    Publication date: August 4, 2011
    Applicant: AMGEN INC.
    Inventors: Sean P. Brown, Paul Dransfield, Xiaohui Du, Zice Fu, Jonathan Houze, XianYun Jiao, Sujen Lai, An-Rong Li, Jiwen Liu, Zhihua Ma, Julio C. Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang, Ming Yu, Liusheng Zhu
  • Modulators of cellular adhesion
    Patent number: 7989626
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: August 2, 2011
    Assignee: SAR code Corporation
    Inventors: Wang Shen, Kenneth Barr, Johan D. Oslob, Min Zhong
  • Biaryl carboxylic acid apoptosis promoters
    Patent number: 7989656
    Abstract: The present invention relates to biaryl carboxylic acid compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing these compounds and methods of treating diseases which express the Mcl-1 protein.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: August 2, 2011
    Assignee: Abbott Laboratories
    Inventors: Michael D. Wendt, Hong Ding, Sheela A. Thomas, Steven W. Elmore, Wang Shen, Daniel A. Dickman, David Augeri
  • Compositions and Methods for Treatment
    Publication number: 20110165228
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 21, 2011
    Publication date: July 7, 2011
    Applicant: SARcode Corporation
    Inventors: John BURNIER, Thomas GADEK, Min ZHONG, Wang SHEN, Johan D. OSLOB, Kenneth BARR
  • Compositions and Methods for Treatment
    Publication number: 20110165229
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 21, 2011
    Publication date: July 7, 2011
    Applicant: SARcode Corporation
    Inventors: John BURNIER, Thomas GADEK, Min ZHONG, Wang SHEN, Johan D. OSLOB, Kenneth BARR
  • Compounds and methods useful for treating asthma and allergic inflammation
    Patent number: 7960567
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: June 14, 2011
    Assignee: Amgen Inc.
    Inventors: Matthew Brown, Michael G. Johnson, An-Rong Li, Jiwen Liu, Sarah E. Lively, Julio C. Medina, Wang Shen, Xuemei Wang, Yingcai Wang
  • Modulators of Cellular Adhesion
    Publication number: 20110124625
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Type: Application
    Filed: February 4, 2011
    Publication date: May 26, 2011
    Applicant: SARcode Corporation
    Inventors: Wang Shen, Kenneth Barr, Johan D. Oslob, Min Zhong
  • Modulators of Cellular Adhesion
    Publication number: 20110124669
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Type: Application
    Filed: February 4, 2011
    Publication date: May 26, 2011
    Applicant: SARcode Corporation
    Inventors: Wang Shen, Kenneth Barr, Johan D. Oslob, Min Zhong
  • Modulators of cellular adhesion
    Patent number: 7928122
    Abstract: The present invention provides compounds having formula (I); and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: April 19, 2011
    Assignee: SARcode Corporation
    Inventors: Wang Shen, Kenneth Barr, Johan D. Oslob, Min Zhong
  • Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders
    Publication number: 20100298367
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: March 4, 2009
    Publication date: November 25, 2010
    Inventors: Sean P. Brown, Paul J. Dransfield, Jonathan Houze, Todd J. Kohn, Jiwen Liu, Julio Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Ming Yu, Liusheng Zhu
  • APOPTOSIS PROMOTERS
    Publication number: 20100234456
    Abstract: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds and methods of treating diseases during which are expressed the Mcl-1 protein are disclosed.
    Type: Application
    Filed: May 25, 2010
    Publication date: September 16, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Michael D. Wendt, Hong Ding, Sheela A. Thomas, Steven W. Elmore, Wang Shen, Daniel A. Dickman, David Augeri
  • Modulators of cellular adhesion
    Patent number: 7790743
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof; wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof; and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: September 7, 2010
    Assignee: SARcode Corporation
    Inventors: Wang Shen, Kenneth Barr, Johan D. Oslob, Min Zhong
  • N-acylsulfonamide apoptosis promoters
    Patent number: 7754886
    Abstract: N-Benzoyl arylsulfonamides having the formula are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.
    Type: Grant
    Filed: February 3, 2009
    Date of Patent: July 13, 2010
    Assignee: Abbott Laboratories
    Inventors: David J. Augeri, Steven A. Baumeister, Milan Bruncko, Daniel A. Dickman, Hong Ding, Jurgen Dinges, Stephen W. Fesik, Philip J Hajduk, Aaron R Kunzer, William J. Mcclellan, David D. Nettesheim, Thorsten K. Oost, Andrew M. Petros, Saul Howard Rosenberg, Wang Shen, Sheela A. Thomas, Xilu Wang, Michael D. Wendt